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The eﬀectiveness of lifestyle interventions within secondary prevention of coronary heart disease (CHD) remains unclear. This
systematic review aimed to determine their eﬀectiveness and included randomized controlled trials of lifestyle interventions, in
primary care or community settings, with a minimum follow-up of three months, published since 1990. 21 trials with 10,799
patients were included; the interventions were multifactorial (10), educational (4), psychological (3), dietary (1), organisational
(2), and exercise (1). The overall results for modifiable risk factors suggested improvements in dietary and exercise outcomes but
no overall eﬀect on smoking outcomes. In trials that examined mortality and morbidity, significant benefits were reported for total
mortality (in 4 of 6 trials; overall risk ratio (RR) 0.75 (95% confidence intervals (CI) 0.65, 0.87)), cardiovascular mortality (3 of
8 trials; overall RR 0.63 (95% CI 0.47, 0.84)), and nonfatal cardiac events (5 of 9 trials; overall RR 0.68 (95% CI 0.55, 0.84)). The
heterogeneity between trials and generally poor quality of trials make any concrete conclusions diﬃcult. However, the beneficial
eﬀects observed in this review are encouraging and should stimulate further research.
1. Introduction
The World Health Organisation has stated that, since 1990,
more people worldwide have died from coronary heart
disease (CHD) than any other cause [1]. Further, they
reported that 80% to 90% of people dying from CHD had
one or more major risk factors associated with lifestyle.
In the UK, more than 90,000 deaths per year are due
to CHD, and although death rates are falling they are still
among the highest in western Europe [2].
Cardiac rehabilitation (CR) programmes were initiated
in the 1960s when the benefits of mobilisation and physical
activity (PA) following lengthy hospital stays for CHD
became known [3]. Since then, secondary prevention has
become an essential aspect of care of the patient with CHD
[4]. Research has shown that lifestyle change, including PA,
a healthy diet, and smoking cessation, alters the course
of CHD [5–7], and so disease prevention measures have
been designed to focus on a range of lifestyle factors.
Indeed, cardiac rehabilitation and secondary prevention
programmes have developed from focusing on exercise alone
to becoming multidisciplinary and encompassing baseline
patient assessments, nutritional counselling, risk factor man-
agement (i.e., lipids, hypertension, weight, diabetes, and
smoking), psychosocial and vocational counselling, and PA
advice and exercise training, in addition to the appropriate
use of cardioprotective drugs [4].
Multidisciplinary measures are advocated by govern-
ments around the world, and in the UK the National Institute
for Clinical Excellence (NICE) set out a series of guidelines in
2007 for care of patients who had had amyocardial infarction
(MI) [8]. The guidelines covered secondary prevention in
primary and secondary care and were not focused solely
on lifestyle interventions. They did, however, incorporate
PA, diet, smoking, and drug therapy and were based on
systematic reviews of the best available evidence. Priority
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recommendations, considered to have the most important
eﬀect on patient care and outcomes, included that on
discharge from hospital every MI patient should have had
a confirmed diagnosis of acute MI, results of investigations,
future management plans, and advice on secondary preven-
tion. Also, NICE highlighted the importance of advice being
given regarding regular PA in the form of 20–30 minutes of
exercise per day to the point of slight breathlessness. Patients
should also be advised to stop smoking, eat a Mediterranean
style diet rich in fibre, fruit, vegetables, and fish, and follow a
treatment regime with a combination of ACE (angiotensin-
converting enzyme) inhibitors, aspirin, beta-blockers, and
statins.
However, despite the evidence that positive lifestyle
changes bring about improved outcomes, results from
a number of secondary prevention initiatives have been
disappointing. In a systematic review of multidisciplinary
secondary prevention programmes McAlister et al. [9]
reported that although some beneficial impact was achieved
on processes of care, morbidity, and mortality, questions
remained regarding the duration and frequency of inter-
ventions and the best combination of disciplines within an
intervention.
The EUROASPIRE (European Action on Secondary and
Primary Prevention by Intervention to Reduce Events) sur-
veys by the European Society of Cardiology have shown that
the adoption of cardiovascular disease prevention measures
as part of daily clinical practice was wholly inadequate
[10] and that unhealthy lifestyle trends are continuing. The
authors commented on the diﬃculty experienced by adults
in changing behaviour despite having a life threatening dis-
ease and that continued professional support was imperative
if this was to be achieved.
Few previous reviews of secondary prevention inter-
ventions have been published. McAlister et al. [9] carried
out a systematic review of RCTs of secondary prevention
interventions, published in 2001, and analysed 12 studies.
Jolliﬀe et al. [11] analysed only exercise interventions in
secondary prevention, and Rees et al. [12] reviewed psycho-
logical interventions. To our knowledge no comprehensive
systematic review has been undertaken since 2001 of the
eﬀects of diet, exercise, and other lifestyle factors in the
secondary prevention of CHD. We therefore performed
a systematic review of randomised controlled trials to
determine the eﬀectiveness of lifestyle interventions for the
secondary prevention of CHD.
2. Methods
This was a systematic review carried out using Cochrane
Collaboration methodology [13].
2.1. Participants. We included male and female adults of
all ages (aged 18+) with a diagnosis of CHD. Patients
included those who had experienced a myocardial infarction
(MI), coronary artery bypass graft (CABG), or percutaneous
transluminal coronary angioplasty (PTCA) and those with
angina pectoris and coronary artery disease defined by
angiography. For the purposes of this review we excluded
patients who had had a heart transplant, heart valve surgery,
or heart failure, unless it was clearly specified that the cause
related to CHD.
2.2. Interventions. We have included interventions with a
lifestyle and/or behaviour change focus designed for the
secondary prevention of CHD, incorporating one or a
combination of exercise and diet. Interventions may be
categorized as follows.
(1) Dietary.
(2) Exercise.
(3) Psychological.
(4) Educational.
(5) Multifactorial.
(6) Organisational (e.g., case management).
2.3. Exclusions. We have excluded from this review studies
which were not randomized controlled trials, focused on
primary prevention, involved patients with multiple diseases
and/or outcomes which were related to diseases other than
CHD, involved patients in a hospital in-patient setting,
focused on drug therapy, had short (less than three months)
or no follow-up, or reported outcomes which were not
the focus of this review (see “Types of outcome measures”
section) such as depression, cost-eﬀectiveness, or service
delivery.
2.4. Study Duration. Trials were included in this review if
they reported a minimum postintervention follow-up of
three months to allow some change to take place.
2.5. Settings. For the purposes of this review, interventions
have been considered to have been delivered in primary
care according to the definition of primary care as stated
by the Committee on the Future of Primary Care at the
Institute of Medicine in the United States: “Primary care
is the provision of integrated, accessible healthcare services
by clinicians who are accountable for addressing a large
majority of personal healthcare needs, developing a sustained
partnership with patients, and practicing in the context of
family and community” [14]. Interventions are delivered in
primary care by clinicians who are “generally considered to
be physicians, nurse practitioners and physical assistants”
and “a broader array of individuals in a primary care team”
[14]. In the care of CHD patients, the primary care teammay
include general practitioners, practice nurses, community
pharmacists, community and public health nurses, dieti-
cians, occupational therapists, and physiotherapists.
(i) Interventions have been included in the review if they
have been delivered in primary care or community
settings by primary care clinicians or clinicians whose
normal roles may be within secondary care, for
example, community hospitals, or tertiary care, for
example, general hospitals.
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(ii) We have excluded from this review studies of inter-
ventions undertaken primarily within secondary or
tertiary care settings by clinicians or care teams
whose relationship with patients is not long term or
ongoing.
2.6. Comparators. In the included studies, the comparators
are “normal care” or “usual care,” meaning standard clinical
care or standard care given by a general practitioner (GP).
2.7. Types of Outcome Measures. All or any number of the
following.
Primary Outcomes
(i) All-cause mortality.
(ii) Cardiac mortality.
(iii) Nonfatal cardiac events.
(iv) Hospital admissions (cardiac related/and all-cause if
available).
Secondary Outcomes
(i) Diet (e.g., measured by fibre, fruit, and veg quantity).
(ii) Exercise (e.g., frequency, duration).
(iii) Blood pressure (BP); systolic BP (SBP); diastolic BP
(DBP).
(iv) Blood lipid levels (high density lipoprotein choles-
terol (HDL-chol), low density lipoprotein cholesterol
(LDL-chol)).
(v) Smoking behavior.
(vi) Health related quality of life (QOL).
(vii) Self eﬃcacy.
(viii) Medication adherence.
Only outcomes measured using a validated instrument were
included.
2.8. Search Methods for Identification of Studies. We searched
electronic databases Medline, Cinahl, and Embase for
English language randomized trials in humans published
since 1990. The search method for Medline is detailed below;
it was modified as appropriate for Cinahl and Embase.
Reference lists of review articles were also searched.
2.9. Medline Search Method. Selecting an Advanced Ovid
search, the keyword “lifestyle” was inserted and the box
ticked to select “Map term to subject heading.” After selecting
“Search” a new page was presented entitled “Mapping
Display.” Options indicating the Subject Headings “Life
Style” and “lifestyle.mp. search as keyword” were chosen and
“Continue” selected. This allowed further keywords to be
entered.
The same process was followed for the keywords “exer-
cise,” “physical activity,” and “diet.” In each case only the
keyword as a subject heading and as a keyword were selected
on the Mapping Display page.
A fifth search was commanded by using all four keywords
above separated by the Boolean operator “OR.” This was
done by selecting “click to expand” the “Search History” box,
ticking each of the four boxes relating to the keywords, and
selecting “Combine selections with OR.”
A sixth search term “secondary prevention” was added
as a keyword in same way as above. A seventh “coronary
heart disease” was inserted, then its abbreviation “CHD”
and four conditions related to it and their abbreviations,
where appropriate, all as separate keywords: “myocardial
infarction,” “MI,” “coronary artery bypass graft,” “CABG,”
“percutaneous transluminal coronary angioplasty,” “PTCA,”
and “angina pectoris.” This group incorporating coronary
heart disease and related conditions involved a total of nine
separate searches, and they were together inserted as a 16th
search, with each term separated by “OR.” This was done, as
above, by expanding the search history, selecting the relevant
boxes beside keywords and selecting “Combine selections
with OR.”
The three components of the search were put together in
the following way.
On the search history page, search five was selected by
clicking on the box beside it (Lifestyle.mp. or Life Style/OR
Exercise.mp. or Exercise/OR Physical activity.mp. ORDiet/or
diet.mp.). Search six was then selected (Secondary preven-
tion.mp. or Secondary Prevention/), and search 16 (Coro-
nary heart disease.mp. or Coronary Disease/OR CHD.mp.
OR Myocardial infarction.mp. or Myocardial Infarction/OR
MI.mp OR Coronary Artery Bypass/or coronary artery
bypass graft.mp. OR CABG.mp. OR Percutaneous trans-
luminal coronary angioplasty.mp. or Angioplasty, Translu-
minal, Percutaneous Coronary/OR PTCA.mp. OR Angina
pectoris.mp. or Angina Pectoris/). The option “Combine
selections with AND” was selected.
This gave search 17. Search 17 was selected by ticking
the box, and limits were imposed in an eﬀort to narrow
the search. Below the search results, within the “Limits”
options, “English language,” “Humans,” and “Publication
Year-1990 to Current” were selected. “Additional Limits” was
then selected, search 17 was selected, and in the “Age Groups”
options “All Adult (19 plus years)” was selected. No other
limits were imposed. Then, “Limit A Search” was selected.
To refine the search further, terms relating to a ran-
domized controlled trial study design were inserted. The
terms entered were randomized controlled trial.mp. or
Randomized Controlled Trial/, controlled clinical trial.mp.
or Controlled Clinical Trial/, random allocation.mp. or
Random Allocation/, double blind method.mp. or Double-
Blind Method/, single blind method.mp. or Single-Blind
Method. Each of these terms was combined with “OR,”
giving search 24.
Selecting search 18 and search 24, and combining them
with “AND” gave the final selection. The Medline search
strategy is detailed in the Appendix.
2.10. Data Analysis. From the searching, titles and abstracts
were screened by two reviewers (MC, JC), and potentially
relevant references were retrieved. The two reviewers (MC,
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Figure 1: Screening and selection of studies of interventions for secondary prevention of coronary heart disease.
JC) then independently selected trials to be included in the
review. Reference lists of relevant systematic reviews were
also screened for potential papers to include.
After the final selection of trials was agreed upon,
data including study characteristics, outcome measures and
results were extracted.
In addition, the quality of trials was assessed in relation to
randomization method, loss to follow up, intention to treat
analyses, and blinding measures.
Dichotomous outcomes for each study have been
expressed as risk ratios, where appropriate, and 95% confi-
dence intervals (CIs). Meta-analyses were performed using
random eﬀects models, and data were presented as forest
plots using Revman software [15]. We were only able to
perform meta-analysis on three outcomes—total mortality,
cardiovascular mortality, and nonfatal cardiac events.
Continuous variables have been expressed as the dif-
ference between intervention and control groups at study
completion and the standard deviation diﬀerence where
reported.
3. Results
3.1. Study Selection and Evaluation. Figure 1 shows the
selection, screening, and identification of studies for this
review. Of the 266 papers originally identified through
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searching the three electronic databases, we identified 39
that were potentially eligible for inclusion, and full text
versions of these studies were retrieved and assessed. Twelve
of the 39 papers were excluded because they included diseases
other than CHD, were drug trials, did not focus on lifestyle,
were not randomized controlled trials, had a short follow-
up period, were conducted within a hospital in-patient
setting, had outcomes which were not of interest, or were
retrieved more than once from the three search engines. Two
papers were added after screening reference lists of relevant
systematic reviews, and one trial was added which reported
diﬀerent outcomes of an identical study which emerged in
our searches (Figure 1).
3.2. Description of Studies. Table 1 shows summary data
of 30 papers from the 21 randomised controlled trials
(RCTs) found to be eligible for this review [16–45]. We
have presented them in the six categories described in the
“Methods” section (exercise, dietary, psychological, edu-
cational, multifactorial, and organisational). The category
which had the largest number of trials was multifactorial (10
in total). We also found one which focused on exercise only,
one dietary intervention, three which had a psychological
approach, four educational, and two organisational.
In all the trials except where stated, patients randomised
to the control group received usual care, which was not
defined by every study but usually meant standard clinical
care or standard care given by a GP.
3.2.1. Study Characteristics. The studies varied greatly in
terms of sample size, duration, and intervention elements;
however all involved patients of a similar age group (older
adults) with CHD.
The sample size of trials ranged from 48 [41] to 3241
[21], and study duration ranged from three months [19, 43]
to four [33] and five years [41]. Follow-up analyses varied
too, ranging from three months [19] to 15 years [45].
3.2.2. Settings. We found much variation in study setting.
Astengo et al. [16] reported a home-based exercise interven-
tion while two studies incorporated initial short residential
stays to deliver an intensive educational programme. Lisspers
et al. [26] conducted a four-week stay at an intervention
unit located in a rural part of northern Sweden, followed
by a structured 11-month programme consisting of self-
recording of lifestyle behaviours and contact with the
patients’ personal coaches. It was not clear whether the
intervention unit was part of a hospital. Ornish et al. [41]
organised a week-long residential stay at a hotel to educate
patients on diet, exercise, and stress, followed by twice-
weekly group support meetings for five years. The Vestfold
Heartcare Study Group [28] conducted an initial six-week
“Heart School” at a hospital rehabilitation centre, although
it was unclear whether this was residential. Heart School
involved physiotherapist-led PA, stress reduction education
and lifestyle counselling followed by nine weeks of twice-
weekly exercise, and then meetings every three months for
two years. No other trial contained a residential element.
3.2.3. Intervention Intensity. Some studies were of intensive
interventions. Salminen et al. [25] delivered nurse-led lec-
tures, lasting up to two hours each, once a month for 16
months. In addition, eight group meetings were organised
throughout this period, six exercise sessions, and three social
events.
Less intensive programmes, in which patients were
encouraged to self-manage their lifestyle behaviour change,
included those reported by Murphy et al. [17] and Cupples
and McKnight [22, 23], in which patients were seen every
four months.
Another less intensive intervention, the Lyon Diet Heart
Study [32, 33], involved a one-hour education session with a
cardiologist and dietician, followed by a repeat visit at eight
weeks and annually thereafter.
3.2.4. Professional Involvement. The interventions included
in this review involved a range of clinical and other
healthcare staﬀ including doctors, nurses, physiotherapists,
psychologists, dieticians, and social workers. Seven of the
21 trials were led by nurses, mainly based in primary care.
De Lorgeril et al. [32, 33] reported a trial conducted by
a cardiologist and dietician. Four studies were GP-led, one
conducted by a physiotherapist and one nutritionist-led.
Other studies involved a variety of professional input.
3.3. Risk of Bias in Included Studies. The methodological
quality of the included studies is presented in Table 2. The
quality of the trials, in terms of themethod of randomisation,
whether groups were similar at baseline, losses to follow up,
whether intention to treat analyses were used and blinding of
outcome assessors, is as reported in the papers.
In seven of the 21 original studies (excluding follow-
up papers), the randomisation method was not clearly
described. In six of these trials, the method was not stated
at all [16, 25, 26, 39, 43, 45]. The majority of the remain-
ing studies described various randomisation techniques
including the use of computer-generated random numbers,
random numbers tables, and sealed envelopes. Lewin et al.
[29] used block randomisation, while Carlsson [42] allocated
patients in groups of 20. Murphy et al. [17] used cluster
randomisation because their intervention was aimed to
alter practitioners’ behaviour which could contaminate their
interactions with control patients.
Loss to follow up was not reported by some authors.
Where it was reported, it was defined diﬀerently. Some
authors included as losses to follow up deaths and with-
drawals due to poor health, while others defined it as people
who could not be accounted for or contacted at follow-up.
Follow-up as a quality marker relates only to original studies
and varied considerably for longer-term follow-up studies as
would be expected.
Thirteen of the 21 studies stated that analyses were
conducted using intention to treat principles. The Vestfold
Heartcare Study Group [28] used the last recorded value of a
variable from the previous visit if there were missing data.
Only seven out of 21 studies reported that outcome
assessors were blind to group allocation. Overall, the quality
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so
u
gh
t
to
co
rr
ec
t
an
y
m
is
u
n
de
rs
ta
n
di
n
g
of
ill
n
es
s.
R
is
k
fa
ct
or
s
di
sc
u
ss
ed
;h
ow
to
re
du
ce
th
es
e
th
ro
u
gh
go
al
se
tt
in
g
an
d
pa
ci
n
g;
pa
ti
en
ts
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ke
d
to
pr
ac
ti
ce
re
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xa
ti
on
u
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n
g
th
e
ta
pe
ea
ch
da
y.
N
u
rs
e
co
n
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ct
ed
pa
ti
en
t
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ph
on
e
at
en
d
of
w
ee
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1,
4,
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d
12
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d
pr
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se
d
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e
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h
ie
ve
m
en
t
of
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h
in
g
go
al
s,
di
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Li
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.
[2
6]
(1
99
9)
,
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ed
en
87
pa
ti
en
ts
w
it
h
at
le
as
t
1
si
gn
ifi
ca
n
t
co
ro
n
ar
y
st
en
os
is
su
it
ab
le
fo
r
P
C
I
an
d
at
le
as
t
1
ad
di
ti
on
al
cl
in
ic
al
ly
in
si
gn
ifi
ca
n
t
co
ro
n
ar
y
le
si
on
.
I
(n
=
46
):
53
(7
);
C
(n
=
41
):
53
(7
).
I:
80
%
;
C
:8
8%
.
C
V
m
or
ta
lit
y,
n
on
fa
ta
lC
V
ev
en
ts
,
di
et
(q
u
es
ti
on
n
ai
re
),
PA
(q
u
es
ti
on
n
ai
re
),
sm
ok
in
g
(q
u
es
ti
on
n
ai
re
),
Q
O
L
(q
u
es
ti
on
n
ai
re
:A
P-
Q
LQ
).
A
t
co
m
pl
et
io
n
of
12
-m
on
th
in
te
rv
en
ti
on
.
Li
ss
pe
rs
et
al
.
[2
7]
(2
00
5)
:
24
,3
6
an
d
60
m
on
th
s
fr
om
ba
se
lin
e.
12
-m
on
th
in
te
rv
en
ti
on
:
n
u
rs
e-
le
d.
4-
w
ee
k
re
si
de
n
ti
al
st
ay
at
in
te
rv
en
ti
on
u
n
it
:i
n
te
n
se
gr
ou
p
an
d
in
di
vi
du
al
h
ea
lt
h
ed
u
ca
ti
on
an
d
tr
ai
n
in
g;
st
re
ss
m
an
ag
em
en
t,
di
et
,e
xe
rc
is
e,
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ok
in
g;
fo
llo
w
ed
by
11
-m
on
th
st
ru
ct
u
re
d
m
ai
n
te
n
an
ce
ph
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e;
re
gu
la
r
co
n
ta
ct
w
it
h
sp
ec
ia
lly
as
si
gn
ed
n
u
rs
e
th
ro
u
gh
m
ai
la
n
d
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on
e
ca
lls
.P
er
so
n
al
lif
es
ty
le
go
al
s
se
t,
di
ar
ie
s
ke
pt
of
ev
er
yd
ay
lif
es
ty
le
be
h
av
io
u
r.
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.
[2
5]
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5)
,
Fi
n
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n
d
22
7
pa
ti
en
ts
w
it
h
C
H
D
.
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=
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:
m
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es
72
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fe
m
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es
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.5
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);
C
(n
=
10
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:
m
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es
72
.6
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fe
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75
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).
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%
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C
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.
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ie
t
(p
at
ie
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t
in
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ie
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at
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ta
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an
d
H
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es
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ro
l.
A
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of
16
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th
in
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en
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.
16
-m
on
th
in
te
rv
en
ti
on
:
n
u
rs
e-
le
d.
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le
ct
u
re
s:
90
–1
20
m
in
u
te
s
ea
ch
;p
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ve
n
ti
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C
H
D
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ie
t
an
d
w
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t
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n
tr
ol
,e
xe
rc
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n
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s.
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at
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at
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6
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at
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3
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al
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at
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u
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C
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so
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.
[4
2,
43
]
(1
99
7)
,
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ed
en
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–7
0
ye
ar
s
w
it
h
ac
u
te
M
I,
C
A
B
G
or
P
T
C
A
le
ss
th
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2
w
ee
ks
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dy
.
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ar
ls
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A
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2]
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1
A
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I
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n
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.
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I
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B
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ra
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se
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n
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at
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.
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t
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2]
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4)
,
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K
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8
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h
o
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h
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n
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m
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s.
I
(n
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:
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ea
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ag
e
62
.7
(7
.1
).
C
(n
=
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6)
:
63
.6
(6
.8
).
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%
C
:5
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u
se
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d
C
V
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or
ta
lit
y,
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ar
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es
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PA
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at
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at
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,
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ro
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L,
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se
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u
gs
.
A
t
co
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pl
et
io
n
of
2-
ye
ar
in
te
rv
en
ti
on
.
C
u
pp
le
s
an
d
M
cK
n
ig
h
t
[2
3]
(1
99
9)
:
5
ye
ar
s
fr
om
ba
se
lin
e.
Pa
ti
en
ts
gi
ve
n
pr
ac
ti
ca
la
dv
ic
e
re
la
ti
n
g
to
C
V
ri
sk
fa
ct
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an
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re
vi
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.
[4
4]
(1
99
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,
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u
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ra
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0
su
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it
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os
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ta
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it
h
su
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te
d
M
I.
I
(n
=
21
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:
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(8
);
C
(n
=
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7)
:
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76
%
C
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N
on
fa
ta
lC
V
ev
en
ts
,
h
os
pi
ta
la
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is
si
on
s,
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et
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at
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ta
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ta
l
ch
ol
es
te
ro
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L
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et
io
n
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in
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en
ti
on
.
6-
m
on
th
in
te
rv
en
ti
on
:
G
P-
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ed
ed
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ti
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ti
on
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et
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G
P
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d
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pa
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Pa
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ag
e
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ep
1
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ac
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Fa
t”
ki
t;
qu
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,p
at
ie
n
t
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r
fa
t
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n
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ra
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d
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at
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.
Pa
ck
ag
e
2:
St
ep
s
2
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d
3;
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s
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ev
io
u
s
w
ee
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s
PA
.
Pa
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ag
e
3:
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s
4
an
d
5;
in
fo
rm
at
io
n
on
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lw
al
ki
n
g
gr
ou
ps
.
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th
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n
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er
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t
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th
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ta
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in
g
re
ci
pe
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an
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at
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n
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at
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H
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le
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o
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e
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at
te
m
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ed
,p
at
ie
n
ts
u
rg
ed
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ph
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e
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re
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ir
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g
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fo
rm
at
io
n
.
So
u
th
ar
d
et
al
.
[3
1]
(2
00
3)
,
U
SA
10
4
su
bj
ec
ts
w
it
h
C
H
D
,c
on
ge
st
iv
e
h
ea
rt
fa
ilu
re
or
bo
th
.
I
(n
=
53
):
61
.8
(1
0.
6)
;
C
(n
=
51
):
62
.8
(1
0.
6)
.
I:
68
%
C
:8
2%
N
on
fa
ta
lC
V
ev
en
ts
,
di
et
(M
E
D
FI
C
T
S
di
et
ar
y
su
rv
ey
),
PA
(m
in
/w
k)
,B
P,
to
ta
l,
LD
L
an
d
H
D
L
ch
ol
es
te
ro
l,
tr
ig
ly
ce
ri
de
s.
A
t
co
m
pl
et
io
n
of
6-
m
on
th
in
te
rv
en
ti
on
.
6-
m
on
th
in
te
rv
en
ti
on
:
In
te
rn
et
ba
se
d
ed
u
ca
ti
on
al
pr
og
ra
m
m
e
fo
r
n
u
rs
e
ca
se
m
an
ag
er
s
to
pr
ov
id
e
ri
sk
fa
ct
or
m
an
ag
em
en
t
tr
ai
n
in
g
an
d
ad
vi
ce
.
Pa
ti
en
ts
ac
ce
ss
ed
in
te
rn
et
pr
og
ra
m
m
e
at
le
as
t
on
ce
a
w
ee
k
fo
r
30
m
in
u
te
s,
co
m
m
u
n
ic
at
in
g
w
it
h
ca
se
m
an
ag
er
vi
a
w
eb
si
te
’s
in
te
rn
al
em
ai
ls
ys
te
m
,c
om
pl
et
in
g
ed
u
ca
ti
on
al
m
od
u
le
s
(w
it
h
in
te
ra
ct
iv
e
m
u
lt
ip
le
ch
oi
ce
se
lf
-t
es
ts
),
en
te
ri
n
g
da
ta
(a
t
an
y
ti
m
e)
to
m
on
it
or
pr
og
re
ss
.O
pt
io
n
al
di
sc
u
ss
io
n
s
w
it
h
ot
h
er
pa
rt
ic
ip
an
ts
,r
ew
ar
ds
gi
ve
n
(w
or
th
$0
.5
0
to
$1
.5
0)
fo
r
ac
ti
ve
pa
rt
ic
ip
at
io
n
on
w
eb
si
te
.D
ie
ti
ci
an
av
ai
la
bl
e
to
an
al
ys
e
24
h
ou
r
di
et
re
ca
lls
.
C
as
e
m
an
ag
er
s
an
d
di
et
ic
ia
n
al
so
av
ai
la
bl
e
vi
a
te
le
ph
on
e
an
d
po
st
if
n
ec
es
sa
ry
.
M
ul
ti
fa
ct
or
ia
l
A
lle
n
et
al
.
[3
0]
(2
00
2)
,
U
SA
22
8
pa
ti
en
ts
w
it
h
hy
p
er
ch
ol
es
te
ro
-
la
em
ia
w
h
o
h
ad
C
A
B
G
or
P
C
I.
I
(n
=
11
5)
:
61
.1
(1
0.
3)
;
C
(n
=
11
3)
:
59
.6
(9
.6
).
I:
70
%
;
C
:7
3%
.
D
ie
t
(B
lo
ck
H
ea
lt
h
H
ab
it
s
an
d
H
is
to
ry
),
PA
(A
er
ob
ic
s
C
en
tr
e
qu
es
ti
on
n
ai
re
),
to
ta
l,
H
D
L,
an
d
LD
L
ch
ol
es
te
ro
l,
tr
ig
ly
ce
ri
de
s.
A
t
co
m
pl
et
io
n
of
1-
ye
ar
in
te
rv
en
ti
on
.
1-
ye
ar
in
te
rv
en
ti
on
:
n
u
rs
e
ca
se
m
an
ag
em
en
t:
pl
an
de
vi
se
d
4–
6
w
ee
ks
af
te
r
h
os
pi
ta
l
di
sc
h
ar
ge
in
cl
u
di
n
g
lif
es
ty
le
co
u
n
se
lli
n
g
an
d
re
vi
ew
of
dr
u
g
th
er
ap
y.
Fo
llo
w
-u
p
te
le
ph
on
e
ca
lls
to
re
in
fo
rc
e
co
u
n
se
lli
n
g
an
d
ad
ju
st
dr
u
g
th
er
ap
y
(e
ac
h
pa
ti
en
t
co
n
ta
ct
ed
av
er
ag
e
7
ti
m
es
du
ri
n
g
fo
llo
w
-u
p
ye
ar
);
on
go
in
g
pl
an
se
n
t
re
gu
la
rl
y
to
do
ct
or
.D
ie
t
ad
vi
ce
:<
30
%
of
to
ta
le
n
er
gy
as
fa
t,
<
7%
sa
tu
ra
te
d
fa
t,
<
20
0
m
g
p
er
da
y
ch
ol
es
te
ro
l;
PA
:p
ar
ti
ci
pa
ti
on
in
m
od
er
at
e
in
te
n
si
ty
h
om
e-
ba
se
d
ex
er
ci
se
pr
og
ra
m
m
e;
re
fe
rr
al
to
C
R
;
sm
ok
in
g
ce
ss
at
io
n
ad
vi
ce
an
d
re
la
ps
e
pr
ev
en
ti
on
.
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R
ev
ie
w
of
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re
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w
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en
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en
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ra
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B
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m
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r
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(1
99
8)
B
:
as
C
am
pb
el
lA
A
s
C
am
pb
el
lA
A
s
C
am
p-
be
ll
A
Q
O
L
(S
h
or
t
Fo
rm
(S
F)
36
qu
es
ti
on
n
ai
re
)
A
t
co
m
pl
et
io
n
of
1-
ye
ar
in
te
rv
en
ti
on
.
A
s
C
am
pb
el
lA
M
u
rc
h
ie
et
al
.[
37
]
(2
00
4)
B
:
as
M
u
rc
h
ie
A
A
s
M
u
rc
h
ie
A
A
s
M
u
rc
h
ie
A
Q
O
L
(S
F
36
)
4
ye
ar
s
fr
om
ba
se
lin
e
D
el
an
ey
et
al
.[
38
]
(2
00
8)
:a
t
10
-y
ea
r
fo
llo
w
-u
p
53
1
of
13
43
or
ig
in
al
co
h
or
t
h
ad
di
ed
.
A
ll-
ca
u
se
m
or
ta
lit
y
an
d
co
ro
n
ar
y
ev
en
ts
(n
on
fa
ta
lM
Is
an
d
co
ro
n
ar
y
de
at
h
s)
.
10
ye
ar
s
fr
om
ba
se
lin
e.
G
ia
lla
u
ri
a
et
al
.[
18
]
(2
00
9)
,I
ta
ly
52
pa
ti
en
ts
w
it
h
ac
u
te
m
yo
ca
rd
ia
li
n
fa
rc
ti
on
(A
M
I)
.
I
(n
=
26
):
58
.2
(7
.8
);
C
(n
=
26
):
57
.4
(9
.7
).
I:
85
%
;
C
:8
5%
.
N
on
fa
ta
lC
V
ev
en
ts
,
PA
(c
yc
le
er
go
m
et
er
te
st
),
B
P,
to
ta
l,
LD
L
an
d
H
D
L
ch
ol
es
te
ro
l,
tr
ig
ly
ce
ri
de
s.
A
t
co
m
pl
et
io
n
of
2-
ye
ar
in
te
rv
en
ti
on
.
2-
ye
ar
in
te
rv
en
ti
on
:
ed
u
ca
ti
on
al
an
d
be
h
av
io
u
ra
l;
in
di
vi
du
al
an
d
gr
ou
p.
E
ac
h
pa
ti
en
t
gi
ve
n
bo
ok
le
t
on
ex
er
ci
se
,d
ie
t
an
d
sm
ok
in
g
ce
ss
at
io
n
,
an
d
id
ea
lt
ar
ge
ts
.M
on
th
ly
h
os
pi
ta
lv
is
it
s:
di
et
ar
y
ad
vi
ce
,
re
in
fo
rc
em
en
t
of
h
ea
lt
hy
lif
es
ty
le
s,
ex
er
ci
se
tr
ai
n
in
g
se
ss
io
n
to
60
–7
0%
of
V
O
2
p
ea
k.
G
ia
n
u
zz
ie
t
al
.
[2
1]
(2
00
8)
,
It
al
y
32
41
pa
ti
en
ts
w
it
h
re
ce
n
t
M
I
(w
it
h
in
pa
st
3
m
on
th
s)
.
57
.9
(9
.2
)
86
.3
%
A
ll-
ca
u
se
an
d
C
V
m
or
ta
lit
y,
n
on
fa
ta
l
C
V
ev
en
ts
,d
ie
t
(k
n
ow
le
dg
e/
h
ab
it
s)
,
PA
(q
u
es
ti
on
n
ai
re
),
sm
ok
in
g
(q
u
es
ti
on
n
ai
re
),
B
P,
to
ta
l,
H
D
L
an
d
LD
L
ch
ol
es
te
ro
l,
se
lf
/s
tr
es
s
m
an
ag
em
en
t,
u
se
of
dr
u
gs
.
A
t
co
m
pl
et
io
n
of
3-
ye
ar
in
te
rv
en
ti
on
;
D
at
a
co
lle
ct
ed
at
6
m
on
th
s,
1,
2
an
d
3
ye
ar
s.
3-
ye
ar
in
te
rv
en
ti
on
:
m
u
lt
if
ac
to
ri
al
,c
on
ti
n
u
ed
ed
u
ca
ti
on
al
an
d
be
h
av
io
u
ra
l;
m
on
th
ly
se
ss
io
n
s
fr
om
m
on
th
s
1
to
6,
th
en
ev
er
y
6
m
on
th
s
fo
r
3
ye
ar
s.
E
ac
h
se
ss
io
n
:3
0
m
in
u
te
s
su
pe
rv
is
ed
ae
ro
bi
c
ex
er
ci
se
;
lif
es
ty
le
an
d
ri
sk
fa
ct
or
co
u
n
se
lli
n
g
la
st
in
g
at
le
as
t
1h
ou
r;
re
in
fo
rc
em
en
t
of
pr
ev
en
ti
ve
in
te
rv
en
ti
on
s.
B
oo
kl
et
on
h
ow
to
de
al
w
it
h
ex
er
ci
se
,d
ie
t,
sm
ok
in
g
ce
ss
at
io
n
,a
n
d
st
re
ss
m
an
ag
em
en
t.
Ta
rg
et
s:
ce
as
e
sm
ok
in
g,
ad
op
t
M
ed
it
er
ra
n
ea
n
di
et
,i
n
cr
ea
se
PA
to
at
le
as
t
3h
ou
rs
/w
ee
k
at
60
–7
5%
of
m
ea
n
m
ax
h
ea
rt
ra
te
,m
ai
n
ta
in
B
M
I
of
<
25
,B
P
14
0/
85
,t
ot
al
ch
ol
es
te
ro
l<
20
0
m
g/
dL
,L
D
L
ch
ol
<
10
0
m
g/
dL
,b
lo
od
gl
u
co
se
<
11
0
m
g/
dL
.D
ru
g
tr
ea
tm
en
ts
p
os
it
iv
el
y
re
co
m
m
en
de
d.
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1:
C
on
ti
n
u
ed
.
So
u
rc
e
St
u
dy
po
pu
la
ti
on
M
ea
n
ag
e
(y
ea
rs
)
%
M
en
O
u
tc
om
es
Fo
llo
w
-u
p
In
te
rv
en
ti
on
H
am
al
ai
n
en
et
al
.[
45
]
(1
99
5)
,
Fi
n
la
n
d
37
5
su
bj
ec
ts
w
it
h
M
I.
I
(n
=
18
8)
:
m
ea
n
ag
e
m
en
53
.4
,w
om
en
58
.8
.
C
(n
=
18
7)
:
m
ea
n
ag
e
m
en
53
.0
,w
om
en
58
.4
.
I:
80
%
C
:8
0%
A
ll-
ca
u
se
an
d
C
V
m
or
ta
lit
y,
PA
(c
yc
le
er
go
m
et
er
te
st
),
sm
ok
in
g
(p
at
ie
n
t
in
te
rv
ie
w
s)
,B
P,
ch
ol
es
te
ro
l,
tr
ig
ly
ce
ri
de
s.
15
ye
ar
s
fr
om
ba
se
lin
e.
3-
ye
ar
in
te
rv
en
ti
on
:
op
ti
m
al
m
ed
ic
al
ca
re
,p
hy
si
ca
la
ct
iv
at
io
n
,a
n
ti
sm
ok
in
g,
di
et
ar
y,
ps
yc
h
os
oc
ia
lc
ou
n
se
lli
n
g
le
d
by
so
ci
al
w
or
ke
r,
ps
yc
h
ol
og
is
t,
di
et
ic
ia
n
,p
hy
si
ot
h
er
ap
is
t,
an
d
do
ct
or
s.
In
te
rv
en
ti
on
m
os
t
in
te
n
si
ve
fo
r
3
m
on
th
s
af
te
r
A
M
I,
cl
os
e
co
n
ta
ct
s
w
it
h
te
am
m
ai
n
ta
in
ed
ov
er
3
ye
ar
s.
M
u
rp
hy
et
al
.
[1
7]
(2
00
9)
,
N
or
th
er
n
Ir
el
an
d
an
d
R
ep
u
bl
ic
of
Ir
el
an
d
90
3
su
bj
ec
ts
w
it
h
C
H
D
re
cr
u
it
ed
fr
om
48
ge
n
er
al
pr
ac
ti
ce
s.
I
(n
=
44
4)
:
68
.5
(9
.3
);
C
(n
=
45
9)
:
66
.5
(9
.9
).
I:
70
%
;
C
:7
0%
.
B
P,
to
ta
lc
h
ol
es
te
ro
l,
h
os
pi
ta
la
dm
is
si
on
s,
Q
O
L
(S
F
12
),
di
et
(D
IN
E
qu
es
ti
on
n
ai
re
),
PA
(G
od
in
qu
es
ti
on
n
ai
re
),
sm
ok
in
g
(S
la
n
N
at
io
n
al
Su
rv
ey
of
H
ea
lt
h
an
d
Li
fe
st
yl
es
in
Ir
el
an
d)
.
A
t
co
m
pl
et
io
n
of
18
-m
on
th
in
te
rv
en
ti
on
.
G
P
an
d
n
u
rs
e-
le
d
ta
ilo
re
d
ca
re
pl
an
s
fo
r
pr
ac
ti
ce
s:
tr
ai
n
in
g
in
pr
es
cr
ib
in
g
an
d
be
h
av
io
u
r
ch
an
ge
,a
dm
in
is
tr
at
iv
e
su
pp
or
t,
qu
ar
te
rl
y
n
ew
sl
et
te
r;
Ta
ilo
re
d
ca
re
pl
an
s
fo
r
pa
ti
en
ts
:m
ot
iv
at
io
n
al
in
te
rv
ie
w
in
g,
go
al
se
tt
in
g,
ta
rg
et
se
tt
in
g
fo
r
lif
es
ty
le
ch
an
ge
,i
n
fo
bo
ok
le
t
gi
ve
n
to
ea
ch
pa
ti
en
t,
pr
og
re
ss
re
vi
ew
ed
ev
er
y
4
m
on
th
s.
(S
oc
ia
lc
og
n
it
iv
e
th
eo
ry
u
se
d
to
de
ve
lo
p
tr
ai
n
in
g
in
be
h
av
io
u
r
ch
an
ge
,d
es
ig
n
pa
ti
en
t
in
fo
bo
ok
le
t,
an
d
in
fo
rm
de
ve
lo
pm
en
t
of
ta
ilo
re
d
pa
ti
en
t
ca
re
pl
an
s.
)
O
rn
is
h
et
al
.
[4
1]
(1
99
8)
,
U
SA
48
pa
ti
en
ts
w
it
h
m
od
er
at
e
to
se
ve
re
C
H
D
.
I
(n
=
20
):
57
.4
(6
.4
);
C
(n
=
15
):
61
.8
(7
.5
).
I:
10
0%
C
:8
0%
C
V
m
or
ta
lit
y,
n
on
fa
ta
lC
V
ev
en
ts
,
h
os
pi
ta
la
dm
is
si
on
s,
di
et
(d
ia
ri
es
),
PA
(q
u
es
ti
on
n
ai
re
on
ty
p
e,
fr
eq
u
en
cy
,
du
ra
ti
on
),
B
P,
to
ta
l,
LD
L
an
d
H
D
L
ch
ol
es
te
ro
l,
tr
ig
ly
ce
ri
de
s,
ap
ol
ip
op
ro
te
in
s.
A
t
co
m
pl
et
io
n
of
5-
ye
ar
in
te
rv
en
ti
on
.
5-
ye
ar
in
te
rv
en
ti
on
:
w
ee
k
lo
n
g
ed
u
ca
ti
on
al
re
si
de
n
ti
al
st
ay
at
h
ot
el
(O
rn
is
h
et
al
.,
19
90
).
G
ro
u
p
su
pp
or
t
m
ee
ti
n
gs
,4
h
ou
rs
tw
ic
e
a
w
ee
k.
D
ie
t:
lo
w
fa
t
ve
ge
ta
ri
an
,f
or
at
le
as
t
a
ye
ar
:f
ru
it
,v
eg
et
ab
le
s,
gr
ai
n
s,
le
gu
m
es
,s
oy
be
an
pr
od
u
ct
s;
n
o
an
im
al
pr
od
u
ct
s
ex
ce
pt
eg
g
w
h
it
e
an
d
1
cu
p/
da
y
of
n
on
fa
t
m
ilk
or
yo
gh
u
rt
.S
tr
es
s
m
an
ag
em
en
t
te
ch
n
iq
u
es
;a
dv
is
ed
at
le
as
t
1
h
ou
r/
da
y;
au
di
oc
as
se
tt
e
ta
pe
to
as
si
st
.
E
xe
rc
is
e:
in
di
vi
du
al
pr
es
cr
ip
ti
on
ac
co
rd
in
g
to
ba
se
lin
e
tr
ea
dm
ill
te
st
re
su
lt
s,
m
ai
n
ly
w
al
ki
n
g;
at
le
as
t
3
h
ou
rs
/w
ee
k,
30
m
in
u
te
s
p
er
se
ss
io
n
.
C
lin
ic
al
ps
yc
h
ol
og
is
t-
le
d
gr
ou
p
di
sc
u
ss
io
n
s:
so
ci
al
su
pp
or
t
to
en
co
u
ra
ge
ad
h
er
en
ce
.
R
ed
fe
rn
et
al
.
[1
9]
(2
00
8)
A
,
A
u
st
ra
lia
14
4
ac
u
te
co
ro
n
ar
y
sy
n
dr
om
e
(A
C
S)
su
rv
iv
or
s
n
ot
ac
ce
ss
in
g
st
an
da
rd
ca
rd
ia
c
re
h
ab
ili
ta
ti
on
(C
R
).
I
(n
=
72
):
62
(1
.6
);
C
(n
=
72
):
67
(1
.3
).
I:
74
%
;
C
:7
5%
.
PA
(P
hy
si
ca
lA
ct
iv
it
y
R
ea
di
n
es
s
Q
u
es
ti
on
n
ai
re
(P
A
R
Q
))
,s
m
ok
in
g
(s
el
fr
ep
or
t/
A
ir
m
et
Sc
ie
n
ti
fi
c
M
ic
ro
-s
m
ok
an
al
ys
er
),
B
P,
to
ta
lc
h
ol
es
te
ro
l.
A
t
co
m
pl
et
io
n
of
3-
m
on
th
in
te
rv
en
ti
on
.
R
ed
fe
rn
et
al
.
[2
0]
(2
00
9)
B
:1
2
m
on
th
s
fr
om
ba
se
lin
e
G
P-
le
d
be
h
av
io
u
r
ch
an
ge
in
te
rv
en
ti
on
;1
h
ou
r
in
it
ia
l
co
n
su
lt
at
io
n
,3
m
on
th
s
of
5
ph
on
e
ca
lls
(R
ed
fe
rn
et
al
.,
20
06
)
fo
r
ri
sk
fa
ct
or
ed
u
ca
ti
on
,a
ss
er
ti
ve
n
es
s
tr
ai
n
in
g
an
d
as
se
ss
m
en
t
of
lif
es
ty
le
go
al
s.
M
an
da
to
ry
ch
ol
es
te
ro
ll
ow
er
in
g
m
od
u
le
,i
n
cl
u
di
n
g
h
ea
lt
hy
ea
ti
n
g
an
d
ph
ar
m
ac
ol
og
ic
al
ad
vi
ce
,
an
d
ch
oi
ce
of
2
ot
h
er
m
od
u
le
s
in
cl
u
di
n
g
B
P
lo
w
er
in
g,
sm
ok
in
g
ce
ss
at
io
n
,a
n
d
PA
;c
h
oi
ce
of
m
an
ag
em
en
t
op
ti
on
s
fo
r
ri
sk
fa
ct
or
s
in
cl
u
di
n
g
do
ct
or
-d
ir
ec
te
d,
su
ch
as
a
PA
“s
cr
ip
t”
fr
om
G
P,
h
os
pi
ta
lp
ro
gr
am
m
e,
fo
r
ex
am
pl
e,
ex
er
ci
se
cl
as
s,
in
di
vi
du
al
pr
og
ra
m
m
e,
or
se
lf
-h
el
p.
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1:
C
on
ti
n
u
ed
.
So
u
rc
e
St
u
dy
po
pu
la
ti
on
M
ea
n
ag
e
(y
ea
rs
)
%
M
en
O
u
tc
om
es
Fo
llo
w
-u
p
In
te
rv
en
ti
on
V
es
tf
ol
d
H
ea
rt
ca
re
St
u
dy
G
ro
u
p
[2
8]
(2
00
3)
,
N
or
w
ay
19
7
su
bj
ec
ts
w
it
h
ac
u
te
M
I,
h
os
pi
ta
lis
at
io
n
fo
r
u
n
st
ab
le
an
gi
n
a,
P
C
I,
or
C
A
B
G
.
I
(n
=
98
):
54
(8
);
C
(n
=
99
):
55
(8
).
I:
81
%
;
C
:8
3%
.
H
os
pi
ta
la
dm
is
si
on
s,
di
et
(F
FQ
),
PA
(s
el
f-
re
po
rt
/d
ia
ri
es
),
sm
ok
in
g
(s
el
f-
re
po
rt
),
B
P,
to
ta
la
n
d
H
D
L
ch
ol
es
te
ro
l,
Q
O
L
(S
F
36
),
u
se
of
dr
u
gs
.
A
t
co
m
pl
et
io
n
of
2-
ye
ar
in
te
rv
en
ti
on
.
2-
ye
ar
in
te
rv
en
ti
on
:
6-
w
ee
k
“h
ea
rt
sc
h
oo
l”
in
h
os
pi
ta
l:
PA
w
it
h
ph
ys
io
th
er
ap
is
t:
15
m
in
u
te
s
w
ar
m
-u
p,
20
m
in
u
te
s
w
al
ki
n
g,
10
m
in
u
te
s
co
ol
-d
ow
n
,1
0
m
in
u
te
s
st
re
tc
h
in
g;
ad
vi
se
d
to
ex
er
ci
se
on
th
ei
r
ow
n
ev
er
y
da
y.
E
du
ca
ti
on
se
ss
io
n
s:
tw
ic
e
a
w
ee
k,
2
h
ou
rs
ea
ch
;d
ie
ta
ry
ad
vi
ce
,
sm
ok
in
g
ce
ss
at
io
n
,P
A
co
u
n
se
lli
n
g,
ri
sk
fa
ct
or
m
an
ag
em
en
t,
ps
yc
h
os
oc
ia
lm
an
ag
em
en
t,
m
ed
ic
at
io
n
,s
tr
es
s
re
du
ct
io
n
;
in
di
vi
du
al
co
u
n
se
lli
n
g.
Fo
llo
w
ed
by
9
w
ee
ks
’o
rg
an
is
ed
PA
tw
ic
e
a
w
ee
k
at
gy
m
su
pe
rv
is
ed
by
ph
ys
io
th
er
ap
is
t;
le
ve
li
n
cr
ea
se
d
to
jo
gg
in
g;
gr
ou
p
m
ee
ti
n
gs
ev
er
y
3r
d
m
on
th
th
ro
u
gh
ou
t
2
ye
ar
fo
llo
w
-u
p.
W
al
ln
er
et
al
.
[3
9]
(1
99
9)
,
A
u
st
ri
a
60
pa
ti
en
ts
<
70
ye
ar
s
w
it
h
an
gi
og
ra
ph
ic
al
ly
do
cu
m
en
te
d
C
A
D
an
d
st
ab
le
an
gi
n
a
pe
ct
or
is
;r
ec
ru
it
ed
af
te
r
su
cc
es
sf
u
l
el
ec
ti
ve
P
T
C
A
.
I
(n
=
28
):
58
(8
).
C
(n
=
32
):
60
(7
)
I:
89
%
;
C
:6
9%
.
N
on
fa
ta
lC
V
ev
en
ts
,
di
et
(7
-d
ay
w
ei
gh
te
d
fo
od
re
co
rd
s)
,P
A
(M
in
n
es
ot
a
Le
is
u
re
T
im
e
qu
es
ti
on
n
ai
re
),
B
P,
LD
L
an
d
H
D
L
ch
ol
es
te
ro
l.
M
ea
n
26
m
on
th
s
(r
an
ge
18
–3
1)
af
te
r
ba
se
lin
e.
12
-m
on
th
in
te
rv
en
ti
on
:
n
u
tr
it
io
n
is
t-
le
d.
A
ll
pa
ti
en
ts
at
ba
se
lin
e:
di
et
ar
y
an
d
lif
es
ty
le
ad
vi
ce
:c
h
ol
es
te
ro
l1
00
–1
50
m
g/
da
y,
fi
br
e
≥2
5
g/
da
y,
PA
≥3
ti
m
es
/w
ee
k
fo
r
30
m
in
u
te
s,
sm
ok
in
g
ce
ss
at
io
n
.I
gr
ou
p:
1-
h
ou
r
di
et
ar
y
ad
vi
ce
se
ss
io
n
s
w
it
h
n
u
tr
it
io
n
is
t
w
ee
kl
y
du
ri
n
g
fi
rs
t
m
on
th
,e
ve
ry
2
w
ee
ks
u
n
ti
lm
on
th
3
th
en
m
on
th
ly
u
n
ti
l
en
d
of
in
te
rv
en
ti
on
.
O
rg
an
is
at
io
na
l
Jo
lly
et
al
.[
40
]
(1
99
9)
,U
K
59
7
pa
ti
en
ts
;4
22
w
it
h
M
I
an
d
17
5
w
it
h
n
ew
di
ag
n
os
is
of
an
gi
n
a.
I
(n
=
27
7)
:
63
(1
0)
;
C
(n
=
32
0)
:
64
(1
0)
.
I:
68
%
;
C
:7
4%
.
To
ta
lc
h
ol
es
te
ro
l,
B
P,
PA
(q
u
es
ti
on
n
ai
re
,
w
al
ki
n
g
te
st
),
sm
ok
in
g
(q
u
es
ti
on
n
ai
re
),
B
M
I.
A
t
co
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of many trials was poor with a majority not having blinded
outcome assessors and many not describing the method of
randomisation.
3.4. Eﬀects of Interventions
3.4.1. All-Cause Mortality. Six studies reported total mor-
tality and are presented in Figure 2. Overall, four studies
showed benefits for intervention patients compared to
controls in relation to total mortality. Because of the large
diﬀerences in follow-up periods, we have used data from
the studies which range from 3 to 5 years to allow easier
comparison of studies. For all interventions except two, this
constituted their study endpoint.
Murchie et al. [36] reported a significant survival eﬀect
for intervention patients compared to controls at their 4.7
year follow-up. Within the same study, Delaney et al. [38]
reported that, at 10 years, the observed diﬀerence was no
longer significant between the groups.
Hamalainen et al. [45] reported a significant survival
eﬀect for intervention patients compared to controls at their
4.7 year follow-up.
The I2 test for heterogeneity combined with the Chi2
nonsignificant P value suggests that the level of heterogeneity
between studies is not important.
3.4.2. Cardiovascular Mortality. Eight studies reported car-
diovascular mortality and are presented in Figure 3. Three
studies showed significant survival eﬀects. Data were col-
lected at times ranging from 2 to 5 years. Delaney et al. [38]
reported a 10-year follow-up study but we have presented
their data collected at 4.7 years to allow for easier comparison
with other studies. For the same reason we have used data
reported by Hamalainen et al. [45] at three years of follow-
up instead of the authors’ results at 15 years.
The three studies reporting significant survival eﬀects
were Cupples and McKnight [22], two-year follow-up results
from an educational intervention, De Lorgeril et al. [33],
a Mediterranean diet study with four-year follow-up, and
Hamalainen et al. [45], a trial of amultifactorial intervention.
Hamalainen et al. [45], who reported coronary mortality,
also reported significant survival eﬀects for intervention
patients compared to controls in their 15-year follow-
up study. Delaney et al. [38] reported CV and coronary
deaths at both 4.7- and 10-year follow-up points. However,
the mortality figures were combined with nonfatal MI to
calculate a proportional hazard ratio. Murchie et al. [36],
a paper from the same study at 4.7 years of follow-up,
reported an adjusted hazard ratio of 0.76 for coronary events
(coronary deaths plus nonfatal MIs) (0.58 to 1.00, P = .049).
The I2 test for heterogeneity indicated a moderate level
of heterogeneity across studies.
3.4.3. Nonfatal Cardiac Events. This was reported by nine
studies. In Figure 4, we have presented data for major
nonfatal events (MI, CABG, PCI, coronary angioplasty).
Significant benefits for intervention patients compared to
controls were shown by five studies. Four studies reported
nonfatal events separately [21, 33, 41, 44] while five reported
the number of patients who had an event.
Lisspers et al. [27] included mortality in “event” results,
therefore although they reported figures for various events
and mortality they did not report a separate statistic for
nonfatal events. Delaney et al. [38] reported coronary events
which included coronary deaths and nonfatal MIs; however
separate figures for each variable were not reported.
Gianuzzi et al. [21] reported nonfatal stroke, heart fail-
ure, and angina data but none of the values was significant.
Lewin et al. [29] reported the frequency of angina attack
in number of episodes per week. Intervention group patients
had a reduction of three attacks per week compared to a
reduction of 0.4 attacks among control subjects (P = .016).
In addition to nonfatal MI and coronary revascularisa-
tion, De Lorgeril et al. [33] reported a number of major and
minor secondary endpoints. They calculated risk ratios for
nonfatal AMI combined with CV deaths, major secondary
endpoints (periprocedural infarction, unstable angina, heart
failure, stroke, pulmonary embolism, peripheral embolism)
combined with primary endpoints, and primary and major
secondary endpoints combined with minor secondary end-
points (stable angina, post-PCTA restenosis, and throm-
bophlebitis). Separate risk ratios for nonfatal CV events were
not reported.
In addition to MI, PTCA, and CABG, Ornish et al. [41]
reported the frequency, duration, and severity of angina chest
pain at one year and five years. One significant value out of
three outcomes reported at the two diﬀerent time points each
was reported: chest pain severity (scale 1–7, baseline to one
year: intervention group 1.5 (1.5) to 0.7 (1.2); control group
0.6 (0.8) to 1.4 (1.2); P < .001).
The I2 test for heterogeneity indicated that there may
be substantial heterogeneity across studies so results of this
meta-analysis have to be interpreted with caution.
3.4.4. Hospital Admissions. Five studies reported results
relating to hospital admissions. While there was an overall
trend to reduced admissions in intervention groups, only
one of these studies reported a significant reduction in
intervention patients [17]. The data are presented in Table 3.
3.4.5. Lifestyle Risk Factors. Data relating to lifestyle risk
factors for CHD–diet, PA, and smoking are presented in
Table 4.
Table 5 shows a summary of lifestyle risk findings from
our included studies. For each of the three areas of diet,
exercise, and smoking, we have presented the number of
studies reporting each outcome, the number of outcomes,
and the numbers of significant and nonsignificant values.
Diet. Fifteen studies reported diet as an outcome, with
a total of 51 outcomes. Of these, 39 showed significant
benefits for intervention patients compared to controls in
relation to dietary consumption. These included significant
improvement in specific food intake, such as fat, fibre, sugar,
and cholesterol [28, 30, 33, 34, 39, 41], diet score, diet
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Study or Subgroup
Cupples and McKnight 1999
De Lorgeril 1999
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Heterogeneity: Tau² = 0.00; Chi² = 1.22, df = 5 (P = .94); I² = 0%
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Figure 2: Eﬀect of interventions on all-cause mortality: comparison of intervention versus control groups.
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Figure 3: Eﬀect of interventions on cardiovascular mortality: comparison of intervention versus control groups.
knowledge, and habits [21, 27, 44, 47], and for concern about
dietary habits [43].
PA. Twenty-one studies incorporated PA, with 37 out-
comes. Of these, 20 showed significant improvements for
intervention patients compared to controls. These included
significant improvements in maximal workload and VO2peak
[16, 18, 27]. Eleven studies used validated questionnaires or
patient diaries [17, 20, 23–25, 28, 30, 34, 36, 39, 41]. Four
conducted patient interviews or used questionnaires which
were not reported as validated [21, 40, 43, 44]. Of these, eight
studies reported significant improvements [20, 21, 23, 27, 28,
30, 34, 39].
Smoking. While all studies reported proportions of the
study populations that smoked, only 13 studies reported
smoking as an outcome and five of these reported significant
reductions in smoking behaviours in the intervention groups
[20, 21, 27, 28, 45]. Hamalainen et al. [45] reported a
nonsignificant diﬀerence between intervention and control
groups at one year, but significant at two and three years.
BP. Thirteen studies reported BP as an outcome, and five
reported significant benefits for intervention compared to
control patients [18, 20, 34, 39, 45]. Giallauria et al. [18]
reported significant improvements in SBP and DBP at 12
months and 24 months. Redfern et al. [20] reported signifi-
cant diﬀerence in SBP among intervention compared to con-
trol patients at three months and 12 months. Campbell et al.
[34] collected BP data from medical records and classified it
as being managed according to British Hypertension Society
recommendations if the last recorded measurement was less
than 160/90mmHg or receiving attention. The significant
diﬀerence between intervention and control groups at one
year was no longer observed at four-year follow-up [36].
Wallner et al. [39] found significant improvements in
SBP and DBP in intervention patients compared to controls.
Hamalainen et al. [45] reported significant benefits for
intervention compared to control patients relating to SBP
and DBP at one, two, and three years but not at six or 10
years.
Total Cholesterol and/or Lipid Levels. These outcomes were
reported by 19 studies and 12 demonstrated significant
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Figure 4: Eﬀect of interventions on nonfatal cardiac events: comparison of intervention versus control groups. MIRevasc = elective
myocardial revascularisation, CABG = coronary artery bypass graft, PCI = percutaneous coronary intervention, C/angioplasty = coronary
angioplasty, Cardcatheter = cardiac catheter, PTCA = percutaneous transluminal coronary angioplasty.
benefits for intervention patients. Seven of these 12 studies
reported significant improvements in total cholesterol for
intervention patients compared to controls [18, 20, 21, 30,
41, 42, 45]. Another study found a significant diﬀerence in
total cholesterol between female intervention and control
groups but not male [25].
Low-Density Lipoprotein Cholesterol (LDL-chol). Five studies
reported significant improvements in levels of LDL-chol
among intervention patients compared to controls [18, 30,
39, 41, 42]. Salminen et al. [25] found significant improve-
ments between female intervention and control groups but
not male.
Only one study, that by Giallauria et al. [18], found a
significant improvement in levels of high-density lipoprotein
cholesterol (HDL-chol) among intervention patients com-
pared to controls.
QOL. 10 studies reported quality of life, and four reported
significant benefits for intervention patients—including for
“physical activity factor” [26], physical function [28], and
emotional [44]. Campbell et al. [35] reported five significant
results out of the eight health status domains (physical,
social, role physical, role emotional, and pain).
Self Eﬃcacy. This was reported by only one study. Gianuzzi
et al. [21] reported a significantly better score in intervention
patients compared to controls relating to self/stress manage-
ment at six month follow-up and throughout their study.
Medication. Nine studies reported use of medications, and
six reported significant improvements among intervention
patients compared to controls.
Lewin et al. [29] reported the number of glyceryl
trinitrate pills or puﬀs of sublingual spray taken per day
which were self-reported in a diary by patients. Intervention
patients reported a significant reduction in doses per week
compared to control group patients.
Campbell et al. [34] reported proportions taking aspirin
which was ascertained by postal questionnaire. A signifi-
cantly greater number of intervention patients at one-year
follow-up was taking aspirin compared to controls.
Carlsson [42] found significant diﬀerences between
intervention and control patients in use of statins and
cholestyramine; however it was unclear how this data was
collected.
In the study by Cupples and McKnight [22, 23] trained
health visitors assessed the use of prophylactic drugs for
angina by interviewing patients. At the two- and five-year
follow-ups, a significantly higher number of intervention
patients were using prophylactic medication than controls.
4. Discussion
We have conducted a systematic review of lifestyle inter-
ventions for the secondary prevention of CHD using
Cochrane Collaboration methodology. The review indicates
that lifestyle interventions have mixed eﬀects with some
benefits in relation to total mortality, CV mortality, and
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Table 3: Impact of interventions on hospital admissions.
Study Intervention Control Risk ratio
Murphy∗
Overall:
P = .03Baseline to 18months:
0.3 (0.6) to
0.4 (0.7)
0.4 (0.8) to
0.5 (1.0)
CV:
P = .04At 18 months:
0.14 (0.50) 0.23 (0.7)
Other:
P = .22
0.24 (0.6) 0.32 (0.7)
Vestfold∗∗ 20 33 NS (not significant)
Ornish∗∗∗ 23 44
0.685 (0.012–13.2),
P = .81
Heller∗∗∗∗ 47 60
0.253∗∗∗∗∗
Diﬀ -0.8%
(−10.0–8.4); NS
Delaney∗∗∗∗∗ 7647 8642 P = .998
∗Mean number of admissions per patient (at 18 months).
∗∗20 admissions related to chest pain without evidence of ischaemia among
11 patients in intervention group, 33 admissions among 14 patients in
control group (at 2 years).
∗∗∗Cardiac hospitalisations (at 5 years).
∗∗∗∗Patients with ≥1 hospital readmission (at 6 months).
∗∗∗∗∗Total number of admissions (at 10 years).
nonfatal CV events as well as PA, diet, blood pressure,
cholesterol, QOL, and medication adherence. The review
was restricted to the period after 1990 because the concept
of secondary prevention and methods to promote it are
a relatively recent development in healthcare. Nonetheless,
we found trials of interventions which were heterogeneous,
and this was evidenced by the range of categories into
which they could be classified. Few trials evaluated a single
component of lifestyle, while many assessed the eﬀects of
a complex, multifactorial intervention. Other diﬀerences
between studies included trial quality, intervention setting,
intensity, duration, and length of follow-up.
For all trials the control group was usual medical care.
We excluded trials which evaluated the intervention against a
diﬀerent intervention or other programme which could not
be defined as usual care.
4.1. Eﬀectiveness of Interventions. Overall, a small number
of studies showed a significant reduction in deaths and
nonfatal MIs while several reported positive results relating
to adherence to lifestyle change. Regarding total mortality,
four studies out of the six reporting this outcome showed
significant benefits in the relatively short time scale studied
(3–5 years). The Lyon Diet Heart Study [33] showed a
significant impact on All-cause mortality and fewer deaths
from CV causes among intervention patients compared
to controls. The protective eﬀect of the intervention was
maintained for up to four years. This was a noteworthy result
because patients were seen annually, indicating that they
were able to maintain the diet for long periods alone and
without professional motivation. The other trials showing
significant benefits were of an educational intervention [22]
and two multifactorial [36, 45]. Only three out of eight
studies showed significant results for cardiovascular mortal-
ity. These were a dietary intervention [33], educational [22]
and multifactorial ones [45], all of which had also shown
significant eﬀects on total mortality.
Concerning nonfatal CV events, we presented 16 out-
comes from nine studies. There were significant improve-
ments in five of these trials, which were of dietary [33],
psychological [27], and multifactorial [21, 39, 41] interven-
tions. Of the five studies which reported hospital admissions,
only one, Murphy et al. [17], reported significant benefit for
intervention patients compared to controls, both for overall
and CV admissions.
In terms of risk factors for CHD, these were assessed by
greatly diﬀering methods which made comparison diﬃcult.
Diet, PA, smoking status, blood pressure, and cholesterol
were widely reported, with varying results. In relation
to diet, significant results were reported for the dietary
intervention, one psychological, three educational, and six
multifactorial interventions. Significant results relating to PA
were reported for one exercise trial, one educational, two
psychological, and seven multifactorial. Of the five studies
which showed significant benefits for intervention patients
compared to controls in relation to smoking, four were mul-
tifactorial and one psychological. All five interventions which
showed significant results relating to BP were multifactorial.
Concerning cholesterol and lipid levels, the interventions
which showed significant results were one psychological, one
educational, and eight multifactorial.
In relation to quality of life, one psychological trial
reported a significant benefit for intervention patients
compared to controls, as did one educational and two
multifactorial.
Few trials reported medication intake or adherence.
However, as appropriate therapy is a key aspect of secondary
prevention of CHD [8], this should surely be given greater
consideration. The trials which reported significant results
relating to medication were classified as psychological (one),
multifactorial (two), and educational (three).
Likewise, self-eﬃcacy, a patient’s ability, and confidence
to manage their own condition, was only reported in one
study. This multifactorial intervention reported a significant
outcome for intervention patients compared to controls.
4.2. Relevance of Lifestyle and Risk Factor Modification.
Recent evidence has shown the importance of focusing on
lifestyle to eﬀect positive changes relating to CHD. Bennett
et al. [48] used the IMPACT CHD model to examine the
decline in CHD mortality in Ireland between 1985 and 2000,
and possible reasons for this. The mortality rate fell during
this period by some 47%, representing 3673 fewer observed
CHD deaths. The authors found that 48% of this decrease
was due to a reduction in major risk factors including
smoking and cholesterol levels. Conversely, an upward trend
was seen in obesity, diabetes, and PA which were said to
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Table 5: Summary of lifestyle risk findings.
Outcome
Number
of studies
with this
outcome
Number of
outcomes
Number
significantly
improved
Number of
outcomes with
no significant
diﬀerence
Exercise 21 37 20 17
Diet 15 51 39 12
Smoking 13 20 7 13
Note: we counted Campbell and Murchie as separate studies as the patients
in each were not necessarily the same. Other follow-up studies, Cupples,
Ornish, Vestfold, and Redfern we counted as one study but counted the
outcomes from each time point as diﬀerent outcomes (hence the 20
outcomes for the 13 studies reporting smoking outcomes).
contribute an additional 500 deaths in 2000. These results
were similar to those found by Palmieri et al. [49], who
also used the IMPACT model and investigated the decline
in CHD mortality in Italy between 1980 and 2000. They
concluded that over half of the mortality fall was due to
risk factors, mainly blood pressure and cholesterol, and just
under half was due to medical therapies.
The Lyon Diet Heart Study [33] was the first clinical
trial evidence in support of the Mediterranean diet, which
comprises a high intake of fruit, vegetables, nuts, legumes,
and grains. Other recent evidence has been found supporting
the Mediterranean diet’s protective eﬀect in the secondary
prevention of CHD [50–52]. O’Connor et al. [6] examined
RCTs of cardiac rehabilitation with exercise and found a
moderate reduction of 20% in total and CV mortality after
one year, with a reduced risk maintained for three years after
infarction. In a recent review of interventions incorporating
exercise as part of a cardiac rehabilitation programme, Jolliﬀe
et al. [11] also observed a reduction in total mortality.
Exercise-only interventions resulted in a 27% reduction in
total mortality and 31% reduction in cardiac mortality while
comprehensive rehabilitation reduced mortality to a lesser
extent (26%).
The psychological interventions included in this review
showed small beneficial eﬀects. This is in keeping with sim-
ilar findings in a recent review of 36 RCTs of psychological
interventions by Rees et al. [12] which showed no evidence
of eﬀect on total or cardiac mortality, but found small
reductions in anxiety and depression.
We included two organisational interventions in this
review, and both reported disappointing results. Jolly et al.
[40] investigated a programme to improve communication
between hospital and GP practices using liaison nurses. The
programme was eﬀective in promoting follow-up care of
patients in general practice; however health outcomes were
not improved. Munoz et al. [24] examined an intervention
involving postal reminders sent to patients to encourage
them to visit their GP. Blood pressure and HDL-cholesterol
levels were improved, but no eﬀect was observed on mortal-
ity or morbidity.
4.3. Limitations of the Review. This review has a number of
potential limitations. The relatively small number of studies
which included mortality as an outcome, the heterogeneity
between trials, and poor quality of reporting all arise from
the primary data. Further, imprecise descriptions of the
interventions and the limited data have made it diﬃcult
to determine the benefits of various components of the
interventions. The majority of the population of the inter-
ventions was male and relatively low risk; however greater
benefit could have been derived from the interventions by
higher risk patients who were excluded on the basis of
comorbidity.
The broad range of trials included, and the subsequent
large number discovered in our search, may have made
comparisons diﬃcult. Nonetheless this reflects the current
lack of clarity in respect of the optimal components of
eﬀective interventions for CHD secondary prevention.
4.4. Implications for Practice. We have found that lifestyle
interventions promoting regular PA, a healthy diet, and
adherence to medication have beneficial eﬀects among
patients with CHD. It is therefore reasonable to promote
such a healthy lifestyle to patients similar to those included
in the RCTs we investigated—mainly older adults who had
suﬀered a coronary event. As practitioners endeavour to
achieve target levels of blood pressure and cholesterol by
altering their patients’ prescribed medication, the potential
value of their advice regarding exercise and diet should not
be overlooked.
4.5. Implications for Future Research. Overall, the current
evidence suggests that lifestyle interventions have some
beneficial eﬀects on total and cardiac mortality, morbid-
ity, and on behaviour change in relation to modifiable
cardiac risk factors. Even where little or no eﬀect was
observed relating to mortality or morbidity, some trials
reported benefits in terms of lifestyle behaviour change. That
healthcare education and even small-scale interventions can
lead to healthier lifestyle choices, as shown in this review
and others, should be an encouragement to professionals
in practice. Future studies should be designed carefully,
with attention given to aspects of study quality, which we
addressed in Table 2. For example, RCTs of a cluster design
help to avoid contamination of control patients. Further,
outcomes should be matched to intervention elements.
In addition, it is important to incorporate concealment
of allocation and blinding of outcomes. Maximal follow-
up should be ensured and more consideration given to
the underlying theoretical foundation for the interven-
tion.
However, the fact that more profound and wide reaching
benefits were not seen in our review is surprising considering
that all guidelines focus on the importance of lifestyle
interventions. Future research should perhaps focus on the
components of interventions and what the ideal combination
of measures, intervention intensity, and duration should be.
In addition, investigations into the barriers to lifestyle change
among patients with CHD may shed new light on why some
well-designed and executed interventions have not resulted
in expected benefits.
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Appendix
Medline Search Strategy
(1) Lifestyle.mp. or Life Style/
(2) Exercise.mp. or Exercise/
(3) Physical activity.mp.
(4) Diet/ or diet.mp.
(5) 1 OR 2 OR 3 OR 4.
(6) Secondary prevention.mp. or Secondary Prevention/
(7) Coronary heart disease.mp. or Coronary Disease/
(8) CHD.mp.
(9) Myocardial infarction.mp. or Myocardial Infarction/
(10) MI.mp.
(11) Coronary Artery Bypass/or coronary artery bypass
graft.mp.
(12) CABG.mp.
(13) Percutaneous transluminal coronary angioplasty.mp.
or Angioplasty, Transluminal, Percutaneous Coro-
nary/
(14) PTCA.mp.
(15) Angina pectoris.mp. or Angina Pectoris/
(16) 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR
15.
(17) 5 AND 6 AND 16.
(18) Limit search 17 by English language, humans, 1990-
current and adults all ages (19 plus).
(19) randomized controlled trial.mp. or Randomized
Controlled Trial/
(20) controlled clinical trial.mp. or Controlled Clinical
Trial/
(21) random allocation.mp. or Random Allocation/
(22) double blind method.mp. or Double-Blind Method/
(23) single blind method.mp. or Single-Blind Method/
(24) 19 OR 20 OR 21 OR 22.
(25) 18 AND 24.
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